Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingGlobeNewsWire • 11/09/23
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewsWire • 11/06/23
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsGlobeNewsWire • 10/25/23
Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)GlobeNewsWire • 10/24/23
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerGlobeNewsWire • 10/10/23
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and ImmunotherapyGlobeNewsWire • 09/28/23
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial OfficerGlobeNewsWire • 08/28/23
Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters ManagementGlobeNewsWire • 08/14/23
Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY StudyGlobeNewsWire • 08/09/23
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory CommitteeGlobeNewsWire • 08/08/23
Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023GlobeNewsWire • 08/04/23
Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in OncologyGlobeNewsWire • 08/01/23
Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational HighlightsGlobeNewsWire • 07/28/23
Medicenna Reports Fiscal Year 2023 Financial Results and Operational HighlightsGlobeNewsWire • 06/27/23
Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 04/27/23
Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewsWire • 04/18/23
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual MeetingGlobeNewsWire • 04/17/23
Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY StudyGlobeNewsWire • 03/30/23